3 assets in Composite Lymphoma

Therapeutic assets addressing Composite Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Rituximab Composite Lymphoma	M.D. Anderson Cancer Center	P1/2	B (57)
CD47/SIRPA-BLOCKING AGENT ALX148 Composite Lymphoma	M.D. Anderson Cancer Center	P1/2	CCC (48)
Lenalidomide Composite Lymphoma	M.D. Anderson Cancer Center	P1/2	CCC (48)